Colvera for Detection of Disease Recurrence

Status Completed

Clinical Trial Summary

To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in CRC subjects who are undergoing surveillance for recurrence.

Clinical Trial Description

This is an observational, prospective comparison study, where blood is collected for assay of methylated BCAT1 and IKZF1 DNA and CEA, from subjects who have undergone curative treatment for primary CRC of stages II and III (AJCC) and who are in remission and scheduled for follow-up radiological imaging as part of their surveillance program for recurrence. Participation is for one visit only as part of each subject's surveillance-monitoring schedule. Two K2-EDTA blood tubes and two PAXgene™ tubes will be collected Any evidence of methylated BCAT1 and/or IKZF1 DNA in blood represents a Colvera "positive" result. CEA levels of 5ug/L or higher will represent a "positive" result. Sensitivity and specificity of the Colvera and CEA test will be estimated and compared in a paired fashion in each case where recurrence status has been investigated and determined by the site clinical management team. Blood testing shall be performed and analyzed by qualified staff blinded to clinical status. This is a cross-sectional observational non-significant risk study, and test results will not be used for clinical management, i.e. there will be no interventions in subjects consenting to participate in this Research Study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03706235
Study type	Observational
Source	Clinical Genomics Pathology
Contact
Status	Completed
Phase
Start date	February 1, 2018
Completion date	April 29, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04094688` - Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer	Phase 3
Active, not recruiting	`NCT04474470` - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer	Phase 1/Phase 2
Recruiting	`NCT06050447` - Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Recruiting	`NCT05504252` - METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin	Phase 2
Suspended	`NCT04108481` - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer	Phase 1/Phase 2
Completed	`NCT00597506` - Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus	Phase 2
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT05477836` - Feasibility and Safety of MiWEndo-assisted Colonoscopy	N/A
Recruiting	`NCT05620134` - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/Phase 2
Recruiting	`NCT03715933` - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Phase 1
Recruiting	`NCT04870879` - Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors	N/A
Recruiting	`NCT04773769` - Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas	N/A
Recruiting	`NCT04739072` - Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Recruiting	`NCT06134440` - ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study	N/A
Withdrawn	`NCT03708536` - Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma	Phase 3
Withdrawn	`NCT02413853` - Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer	Phase 2
Completed	`NCT00165217` - Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma	Phase 2
Active, not recruiting	`NCT04457284` - Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer	Phase 2
Suspended	`NCT04111172` - A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma	Phase 2
Not yet recruiting	`NCT06118658` - Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations	Phase 2

Colvera for Detection of Disease Recurrence — NOVA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms